Transgene Biotek reports widening losses and negative equity in FY26
The company's revenue dropped to ₹21.12 lakhs as net losses more than doubled. Litigation with SEBI, ED, and NCLT remains ongoing.
— 1 earlier story on Transgene Biotek Ltd. →What's new
- FY26 revenue fell to ₹21.12 lakhs.
- Net loss widened to ₹165.29 lakhs.
- Negative equity now stands at ₹919.98 lakhs against ₹1,713.68 lakhs in total debt.
Why this matters
The company is in severe operational distress with an unsustainable capital structure. The ongoing legal battles with regulators add a layer of uncertainty that persists well into 2026.
What we're watching
- Outcome of NCLT, SEBI, and ED hearings scheduled for July 2026.
- Any further deterioration in the company's negative equity position.
- Management's ability to service ₹1,713.68 lakhs in debt.
The full read
Transgene Biotek’s FY26 results confirm a path of severe operational distress. Revenue for the year dropped to ₹21.12 lakhs, while the net loss widened to ₹165.29 lakhs from ₹67.61 lakhs in the prior year. The balance sheet is in a precarious state, showing negative equity of ₹919.98 lakhs and total borrowings of ₹1,713.68 lakhs. These figures point to an unsustainable capital structure for the nano-cap company, which currently holds a market capitalization of ₹24 crore. While the auditor provided an unmodified opinion, the company remains entangled in litigation with SEBI, the ED, and the NCLT. These legal proceedings are adjourned until July 2026. The results contain no new surprises for a company already on a distressed trajectory, but they confirm that the underlying financial pressures remain unchanged.
Questions answered
- What is the current state of Transgene Biotek's balance sheet?
- The company reports negative equity of ₹919.98 lakhs and carries total borrowings of ₹1,713.68 lakhs.
- How did the company's financial performance change in FY26?
- Revenue fell to ₹21.12 lakhs, while the net loss widened to ₹165.29 lakhs from ₹67.61 lakhs in the previous year.
- Are there any pending legal issues?
- Yes, the company is involved in ongoing litigation with SEBI, the ED, and the NCLT. Hearings for these matters are adjourned until July 2026.
- Did the auditor raise concerns about these results?
- The auditor issued an unmodified opinion, though the notes to the financial results detail the ongoing regulatory litigation.
Story so far
All notes on TRABI →- 29 May 2026 · 4:05 PM IST Transgene Biotek reports widening losses and negative equity in FY26
- 1d ago Transgene Biotek reports ₹21 lakh revenue as legal battles drag on